Coronavirus / COVID

Investigators tested bamlanivimab monotherapy as well as in combination with etesevimab.

In the most recent trials of tocilizumab for COVID-19, patients with moderate illness benefited but survival rate of severely ill did not improve or worsened.

A discussion surrounding how environmental and behavioral factors can lower immune system responses.

The data from this study has stimulated international efforts exploring the use of the therapy for SARS-CoV-2.

Pre-existing high cholesterol levels have been associated with increased risk for severe COVID-19.

The to-be-reviewed assessment of real-world vaccine recipients suggests 51% greater efficacy with BNT162b2 after 13-24 days.

The European Medicines Agency announced today it has recommended granting a commercial marketing authorization (CMA) to the company for its vaccine.

Previous studies have linked psychiatric disorders in general to an increased risk of dying from the virus.

Data for its phase 3 trial shows differing levels of protection for moderate to severe disease depending on the geographic region.

The findings accompany news that the company is working on new vaccines to address more transmissible SARS-CoV-2 variants.

The US Centers for Disease Control and Prevention shares a similar outlook with the organization.

T cells are part of the immune system and play an important part in the body's protection against viral infections.

Recombination is proposed to be critical for coronavirus diversity and emergence of the SARS-CoV-2 variant.

Moderately ill patients hospitalized with COVID-19 were less likely to require life support after receiving full-dose anticoagulation treatment, according to interim results of a multiplatform randomized trial.

University of Wisconsin, Madison investigators screened 145 student-athletes who were recovering from asymptomatic or mild-to-moderate coronavirus cases.

After setbacks to its own vaccine candidate, the major drug developer has agreed to aide in production for Europe-bound doses.

Unlike the influenza A virus H1N1 2009 pandemic, pregnancy was not identified as a high-risk condition for SARS-CoV-2.

The findings may have important implications on vaccine research and development.

Using the Defense Production Act to aid in the effort remains on the table.

Independent investigators assessed in vitro neutralization potency using the antibody therapy, Regen-Cov, against the B.1.1.7 and B.1.351 strains.

Roughly half the US population is now eligible to get a COVID-19 vaccine, according to health guidelines, but supply cannot keep up with demand.

Cheap, safe, and readily accessible preventative measures that modulate severe disease outcomes are desperately needed.

Preclinical evidence and observations have yielded mixed conclusions, but a new clinical study finds no negative effect to medication continuation.

On November 5, England went into a large scale lockdown to help curb the spread of the virus. This resurgence wasn’t unique to the UK though, but many have questioned the efficacy of such lockdowns, especially second ones.

New systematic review data suggest most patients who test positive without symptoms will remain asymptomatic over time.

A France-based assessment of the IL-1 inhibitor was ended early on the recommendation of the safety monitoring board early this year.

Findings may also provide profound protection for asthma by reducing severity of asthma attacks.

Company announced it will continue developing 2 investigational therapeutics.

The United States and China make up nearly half of the globes vaccinations.

However, there is a six-fold reduction in neutralizing titers in the B.1.351 variant from South Africa, so the company is exploring strategies aimed against new variants.